(Q50920187)

25 March 2018

http://europepmc.org/abstract/MED/26500058

title

Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association. (English)

1 reference

25 March 2018

http://europepmc.org/abstract/MED/26500058

author

Chia-Yi Su

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Michael Hsiao

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Tsu-Yao Cheng

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Jang-Ming Lee

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Y-C Yang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

S-M Huang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

P-W Yang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

C-K Chen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

K-T Hua

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

M-L Kuo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

English

0 references

publication date

26 October 2015

1 reference

25 March 2018

http://europepmc.org/abstract/MED/26500058

published in

Oncogene

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

3387-3398

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Pyruvate kinase M2 is a phosphotyrosine-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Serine is a natural ligand and allosteric activator of pyruvate kinase M2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Pharmacologic activation of PKM2 slows lung tumor xenograft growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Regulation of glycolysis by Raf protein serine/threonine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Structural insight into mechanisms for dynamic regulation of PKM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

HSP90 at the hub of protein homeostasis: emerging mechanistic insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

PKM2 regulates chromosome segregation and mitosis progression of tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

A global view of Hsp90 functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Integration of EGFR inhibitors with radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.397

Guanosine 5'-O-[S-(4-bromo-2,3-dioxobutyl)]thiophosphate and adenosine 5'-O-[S-(4-bromo-2,3-dioxobutyl)]thiophosphate. New nucleotide affinity labels which react with rabbit muscle pyruvate kinase

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26500058

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2015.397

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26500058%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference